Chemical Stock With 20% Growth Guidance and ATBS Expansion to Add to Your Watchlist

Synopsis: Specialty chemical stock with ~20 percent growth outlook driven by ATBS expansion and strong antioxidant demand, supported by diversified industrial chemical portfolio and improving volume momentum across key segments.

The article outlines a company that targets robust growth, which is a leading Indian manufacturer of specialty chemicals and organic intermediaries, commanding a significant global market share in its core products, ATBS and IBB.

With the market capitalization of Rs 13,715 crore, Vinati Organics Ltd’s  closed at Rs 1,323, down 1.40 percent from its previous close. The share of this company gave a negative return of 22 in the last five years.

Management Outlook

• ATBS Capacity Expansion and Demand Recovery The management highlighted that the ATBS (Acrylamide Tertiary Butyl Sulfonic Acid) expansion was completed in October, strengthening production capacity. After some demand pressure in the previous year, ATBS consumption has started improving from April. The company expects volume growth of around 20 percent going forward, supported by better industrial demand trends. ATBS is basically a performance-enhancing chemical used across the oil, water, and cleaning industries.
• Product Mix and Volume Trends In the specialty chemicals portfolio, performance has been mixed across segments. Anti-oxidants recorded strong traction with 25 percent volume growth, while IB and IBB remained largely flat. Overall realizations were slightly lower despite volume growth in select products, indicating some pricing pressure in the market.
• Growth Outlook and Revenue Drivers The company expects steady growth momentum ahead, with ATBS volumes contributing meaningfully from the expanded capacity. Revenue from the new subsidiary is expected to start flowing from October. Anti-oxidants are also projected to deliver around 15 percent revenue growth, supporting overall topline expansion.
• Margin Guidance and FY27 Expectations Management has maintained confidence in sustaining EBITDA margins in the 26–27 percent range for FY27. It also expects overall volume growth of about 15 percent in FY27. Additionally, higher crude oil prices are seen as a positive trigger for ATBS demand, supporting medium-term stability in the business outlook.

Segment-wise Revenue Contribution 

The company’s revenue is fairly diversified across segments, with ATBS contributing around 35 percent of total revenue, making it the largest segment. Butyl phenol accounts for about 15 percent, while antioxidants contribute nearly 10 percent of the overall mix. 

Where IBB forms around 11 percent of revenue, and IB along with HPMTBE (IB derivatives) contributes close to 15 percent. The remaining 15 percent comes from other products, including customized chemicals and additives, supporting overall portfolio diversification. 

The revenue base is fairly diversified, but ATBS remains the largest single contributor at around one-third of total sales. Along with butyl phenol and antioxidants, the top specialty chemical segments form the core growth engine of the business. The remaining revenue comes from IB derivatives, IBB, and other customized chemical products, which provide additional stability and product mix diversification. 

How did the ATBS segment perform in Q4?

The ATBS segment delivered strong performance during the period, recording 30 percent growth in FY25, driven mainly by higher volumes. Demand conditions remained healthy, supported by steady industrial consumption, while operational improvements further strengthened output. The management highlighted that growth was largely volume-led, indicating robust underlying demand trends in the segment.

The company also maintained a strong leadership position in ATBS with a global market share of 60 to 65 percent. Looking ahead, demand is expected to remain strong with continued double-digit growth anticipated in FY26. This reflects sustained momentum in the core business, supported by capacity readiness and stable end-market demand conditions.

Capex on the segment

The company has completed its ATBS capacity expansion, which is scheduled to be fully operational by June 2025. This expansion is aimed at strengthening production capability and meeting rising demand in the ATBS segment, which is one of its key growth drivers. The move is expected to support higher volume growth going forward.

Overall, the company has planned a total capex of around Rs 360 crore for FY26, which includes investments in capacity expansion, new product development, and operational efficiency improvements. In addition, the R&D pipeline is strong, with 3 to 4 new products under development that could trigger the next phase of capex depending on successful trials.

About the Company

Vinati Organics Limited (VOL), incorporated in 1989 and based in Mumbai, is a leading Indian manufacturer of specialty chemicals and organic intermediaries, commanding a 65–70 percent global market share in its core products, ATBS and IBB. It is the world’s largest producer of Isobutyl Benzene (IBB) and 2-Acrylamido-2-methylpropane sulfonic acid (ATBS), serving industries such as pharmaceuticals, water treatment, and personal care across 35+ countries. 

The company’s product portfolio includes IBB chemical, which is used in the manufacturing of ibuprofen-based pain relief medicines, and ATBS chemical, which finds application in oil drilling, water treatment, detergents, and other industrial chemicals.

It also produces aroma chemicals used in perfumes, cosmetics, and fragrances, along with specialty additives that are used in paints, adhesives, and polymer-based applications across industries. 

Financial Highlight: The revenue from operations decreased by 6 percent to Rs 611 crore in Q4 FY26 (Mar 2026) from Rs 648 crore in Q4 FY25 (Mar 2025), and EBIDT remained flat at Rs 183 crore in Q4 FY26 compared to Rs 184 crore in Q4 FY25. Accompanied by a net profit growth of 8 percent to Rs 138 crore in Q4 FY26 from Rs 128 crore in Q4 FY25, resulting in an EPS growth of 8 percent to Rs 13.26 per share in Q4 FY26. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Chemical Stock With 20% Growth Guidance and ATBS Expansion to Add to Your Watchlist appeared first on Trade Brains.